PIPA: A Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination With PAlbociclib, With the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers

Trial Profile

PIPA: A Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination With PAlbociclib, With the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Palbociclib (Primary) ; Pictrelisib (Primary) ; Taselisib (Primary) ; Fulvestrant
  • Indications Breast cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=24) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 19 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top